Artara Therapeutics Inc., of New York, appointed Richard Levy and Gregory Sargen to its board.
Bone Therapeutics SA, of Gosselies, Belgium, appointed Miguel Forte CEO, effective Jan. 1, 2020.
Boston Pharmaceuticals Inc., of Cambridge, Mass., appointed Joanne Beck chief operating officer.
Cerecin Inc., of Singapore, appointed Joseph S. Zakrzewski chair of its board.
Encoded Therapeutics Inc., of South San Francisco, appointed Nancy Boman chief regulatory officer and Monique Bobadilla chief people and culture officer.
Immuneering Corp., of Cambridge, Mass., appointed Scott Barrett chief medical officer.
Kezar Life Sciences Inc., of South San Francisco, appointed Elizabeth Garner to its board.
Kodiak Sciences Inc., of Palo Alto, Calif., appointed Taiyin Yang to its board.
Lodo Therapeutics Corp., of New York, appointed Dale Pfost CEO and chair of its board. It also appointed Steve Colletti senior vice president of R&D, Anthony Colasin senior vice president of business development, Barbara Lindheim consulting vice president of strategic communications and investor relations and Sarajane Mackenzie consulting vice president of human resources and organization development.
Molecular Templates Inc., of Austin, Texas, appointed Corazon Dating Sanders to its board.
Novan Inc., of Morrisville, N.C., appointed Paula Brown Stafford CEO, effective Feb. 2, 2020.
Oncorus Inc., of Cambridge, Mass., appointed Mary Kay Fenton to its board.
Protalix Biotherapeutics Inc., of Carmiel, Israel, appointed Pol F. Boudes and Gwen A. Melincoff to its board, effective Jan. 1, 2020.
Resverlogix Corp., of Calgary, Alberta, appointed Dicky To to its board.
Revive Therapeutics Ltd., of Toronto, elected Michael Frank chair of its board and appointed him CEO. The company also elected Christian Scovenna and Andrew Lindzon to its board.
Syros Pharmaceuticals Inc., of Cambridge, Mass., appointed Mark Alles to its board.
Xencor Inc., of Monrovia, Calif., appointed Dagmar Rosa-Bjorkeson to its board.
Zelluna Immunotherapy AS, of Oslo, Norway, appointed Namir Hassan CEO.